NCT07202403
Iterative Design Trial to Assess Dietary Supplements and Other Aging-targeted Therapies
Enrolling by Invitation
NAAges 18–75InterventionalPreventionAtria Research and Global Health Institute (ARGHI)Investigator-initiated
~10 participants
Updated 2025-10-01 on ClinicalTrials.gov
What's tested:Spermidine
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and tolerability
Measured over Baseline to Day 112
Conditions
Where it's being run
1 sites across 1 statesNew York1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Adults aged 18 to 75
Patients without known significant organ dysfunction, based on standard blood tests within the last year
Exclusion
Patients taking any immunomodulatory medications that the investigator or treating physician believe may alter the immune response to the study agent (e.g. biologic antibodies, immunosuppressants)
Patients actively receiving any therapy that, in the determination of the investigator, may impact the effect of the study agent.
Patients who, in the opinion of the treating investigator, will not be able to follow treatment and defined follow-up
Pregnancy
What this trial measures
- Safety and tolerabilityBaseline to Day 112
Assessment of toxicity of therapeutic intervention. Toxicity will be assessed through adverse event monitoring conducted at clinic visits or by phone, with adverse events evaluated and graded using CTCAE v5.0.